Antibodies as Drugs: Immunological Scaffolds as Therapeutics
Joint with the meeting on Tumor Immunology: Multidisciplinary Science Driving Combination Therapy
February 8—13, 2015 Banff, Alberta, Canada
Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.
While monoclonal antibodies are now an established class of drugs in oncology and inflammation, exciting progress has been recently made on next generation, engineered therapeutic antibodies and alternative immunological scaffolds, with first examples from this class being recently approved by FDA and EMA. The symposium will review progress in this area including lessons learned in the clinic and how this can be applied to new targets and drug candidates. It will cover major areas of activity including: 1) Increasing antibody potency via antibody engineering, better engaging immune effector cells, and improvements in targeted delivery of effectors via fusion proteins and via conjugation of cytotoxic drugs; 2) Applying alternative targeting approaches to increase the therapeutic window, such as pre-targeting and site-specific antibody unmasking; 3) Novel antibodies in areas outside of oncology, including infectious diseases, neurology and chronic inflammation; 4) Engineering antibodies and scaffolds for alternative delivery routes and improved disposition; 5) Clinical progress with multi-specific antibodies; and 6) Recent advances on (i) addressing difficult targets such as GPCRs and ion channels, (ii) alternative immunological scaffolds, and (iii) novel antibody library technologies.